Arbutus Cash Per Share vs Ev To Free Cash Flow Analysis

ABUS Stock

USD 3.76 0.08 2.17%

Arbutus Biopharma financial indicator trend analysis is way more than just evaluating Arbutus Biopharma Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arbutus Biopharma Corp is a good investment. Please check the relationship between Arbutus Biopharma Cash Per Share and its Ev To Free Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arbutus Biopharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

Cash Per Share vs Ev To Free Cash Flow

Cash Per Share vs Ev To Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arbutus Biopharma Corp Cash Per Share account and Ev To Free Cash Flow. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Arbutus Biopharma's Cash Per Share and Ev To Free Cash Flow is -0.35. Overlapping area represents the amount of variation of Cash Per Share that can explain the historical movement of Ev To Free Cash Flow in the same time period over historical financial statements of Arbutus Biopharma Corp, assuming nothing else is changed. The correlation between historical values of Arbutus Biopharma's Cash Per Share and Ev To Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Per Share of Arbutus Biopharma Corp are associated (or correlated) with its Ev To Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Free Cash Flow has no effect on the direction of Cash Per Share i.e., Arbutus Biopharma's Cash Per Share and Ev To Free Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.35

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Cash Per Share

Ev To Free Cash Flow

A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.

Most indicators from Arbutus Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arbutus Biopharma Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arbutus Biopharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

At this time, Arbutus Biopharma's Issuance Of Capital Stock is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 2.32 in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.

Arbutus Biopharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Short Term Debt	Other Liab	Net Tangible Assets
Total Assets		-0.13	0.08	1.0	0.14	-0.73	-0.04	0.76	0.97	0.4	0.75	-0.09	0.32	0.1	0.12	0.97	-0.1	0.27	0.97	0.01	0.74	-0.22	0.21	0.65	0.97	0.9
Other Current Liab	-0.13		0.88	-0.14	0.0	0.14	-0.57	-0.13	-0.28	-0.33	0.23	0.22	0.52	0.72	0.51	-0.25	0.38	0.08	-0.1	0.28	0.24	0.02	-0.37	-0.41	-0.21	0.01
Total Current Liabilities	0.08	0.88		0.05	0.03	0.07	-0.61	-0.01	-0.09	-0.26	0.4	0.22	0.66	0.81	0.64	0.0	0.25	0.23	0.16	0.43	0.4	-0.11	-0.09	-0.05	0.02	0.24
Total Stockholder Equity	1.0	-0.14	0.05		0.14	-0.74	-0.03	0.77	0.96	0.43	0.75	-0.09	0.31	0.09	0.11	0.95	-0.08	0.27	0.95	0.01	0.74	-0.23	0.19	0.63	0.95	0.9
Property Plant And Equipment Net	0.14	0.0	0.03	0.14		0.14	-0.67	-0.1	-0.01	0.07	0.46	-0.3	0.56	0.34	0.62	0.06	0.42	0.28	0.1	0.61	0.47	-0.18	-0.48	0.02	0.02	-0.13
Net Debt	-0.73	0.14	0.07	-0.74	0.14		-0.17	-0.99	-0.7	-0.24	-0.59	-0.11	-0.05	0.12	0.33	-0.69	-0.09	-0.24	-0.66	0.31	-0.58	0.24	-0.25	-0.37	-0.7	-0.67
Retained Earnings	-0.04	-0.57	-0.61	-0.03	-0.67	-0.17		0.09	0.17	0.39	-0.5	0.0	-0.93	-0.9	-0.83	0.06	-0.71	-0.27	-0.06	-0.84	-0.51	0.1	0.55	0.22	0.04	-0.01
Cash	0.76	-0.13	-0.01	0.77	-0.1	-0.99	0.09		0.72	0.23	0.63	0.08	0.14	-0.03	-0.25	0.73	0.13	0.28	0.7	-0.2	0.62	-0.27	0.26	0.43	0.73	0.72
Non Current Assets Total	0.97	-0.28	-0.09	0.96	-0.01	-0.7	0.17	0.72		0.42	0.56	-0.1	0.11	-0.08	-0.07	0.97	-0.29	0.13	0.94	-0.14	0.55	-0.12	0.29	0.66	0.97	0.88
Non Currrent Assets Other	0.4	-0.33	-0.26	0.43	0.07	-0.24	0.39	0.23	0.42		0.26	-0.31	-0.24	-0.41	-0.01	0.33	-0.4	0.23	0.27	-0.22	0.25	-0.29	0.31	0.43	0.28	0.31
Cash And Short Term Investments	0.75	0.23	0.4	0.75	0.46	-0.59	-0.5	0.63	0.56	0.26		-0.06	0.66	0.45	0.52	0.64	0.38	0.5	0.73	0.28	1.0	-0.39	-0.07	0.41	0.63	0.64
Net Receivables	-0.09	0.22	0.22	-0.09	-0.3	-0.11	0.0	0.08	-0.1	-0.31	-0.06		-0.02	0.06	-0.13	-0.16	0.16	-0.04	-0.08	-0.08	-0.04	0.04	0.16	-0.17	-0.09	-0.1
Common Stock Total Equity	0.32	0.52	0.66	0.31	0.56	-0.05	-0.93	0.14	0.11	-0.24	0.66	-0.02		0.93	0.82	0.23	0.62	0.42	0.33	0.83	0.66	-0.25	-0.41	0.02	0.25	0.34
Common Stock Shares Outstanding	0.1	0.72	0.81	0.09	0.34	0.12	-0.9	-0.03	-0.08	-0.41	0.45	0.06	0.93		0.78	0.02	0.57	0.28	0.15	0.8	0.45	-0.11	-0.42	-0.17	0.06	0.23
Short Term Investments	0.12	0.51	0.64	0.11	0.62	0.33	-0.83	-0.25	-0.07	-0.01	0.52	-0.13	0.82	0.78		0.04	0.4	0.36	0.17	0.76	0.53	-0.22	-0.36	0.04	0.02	0.11
Non Current Liabilities Total	0.97	-0.25	0.0	0.95	0.06	-0.69	0.06	0.73	0.97	0.33	0.64	-0.16	0.23	0.02	0.04		-0.22	0.21	0.98	-0.04	0.63	-0.17	0.3	0.71	0.99	0.88
Other Current Assets	-0.1	0.38	0.25	-0.08	0.42	-0.09	-0.71	0.13	-0.29	-0.4	0.38	0.16	0.62	0.57	0.4	-0.22		0.2	-0.15	0.47	0.39	-0.08	-0.45	-0.29	-0.21	-0.11
Other Stockholder Equity	0.27	0.08	0.23	0.27	0.28	-0.24	-0.27	0.28	0.13	0.23	0.5	-0.04	0.42	0.28	0.36	0.21	0.2		0.23	0.27	0.5	-0.98	-0.28	0.24	0.19	0.2
Total Liab	0.97	-0.1	0.16	0.95	0.1	-0.66	-0.06	0.7	0.94	0.27	0.73	-0.08	0.33	0.15	0.17	0.98	-0.15	0.23		0.01	0.72	-0.17	0.25	0.67	0.97	0.89
Property Plant And Equipment Gross	0.01	0.28	0.43	0.01	0.61	0.31	-0.84	-0.2	-0.14	-0.22	0.28	-0.08	0.83	0.8	0.76	-0.04	0.47	0.27	0.01		0.28	-0.13	-0.39	-0.1	-0.03	0.03
Total Current Assets	0.74	0.24	0.4	0.74	0.47	-0.58	-0.51	0.62	0.55	0.25	1.0	-0.04	0.66	0.45	0.53	0.63	0.39	0.5	0.72	0.28		-0.39	-0.07	0.39	0.62	0.63
Common Stock	-0.22	0.02	-0.11	-0.23	-0.18	0.24	0.1	-0.27	-0.12	-0.29	-0.39	0.04	-0.25	-0.11	-0.22	-0.17	-0.08	-0.98	-0.17	-0.13	-0.39		0.21	-0.26	-0.15	-0.15
Short Long Term Debt Total	0.21	-0.37	-0.09	0.19	-0.48	-0.25	0.55	0.26	0.29	0.31	-0.07	0.16	-0.41	-0.42	-0.36	0.3	-0.45	-0.28	0.25	-0.39	-0.07	0.21		0.66	0.25	0.32
Short Term Debt	0.65	-0.41	-0.05	0.63	0.02	-0.37	0.22	0.43	0.66	0.43	0.41	-0.17	0.02	-0.17	0.04	0.71	-0.29	0.24	0.67	-0.1	0.39	-0.26	0.66		0.63	0.63
Other Liab	0.97	-0.21	0.02	0.95	0.02	-0.7	0.04	0.73	0.97	0.28	0.63	-0.09	0.25	0.06	0.02	0.99	-0.21	0.19	0.97	-0.03	0.62	-0.15	0.25	0.63		0.89
Net Tangible Assets	0.9	0.01	0.24	0.9	-0.13	-0.67	-0.01	0.72	0.88	0.31	0.64	-0.1	0.34	0.23	0.11	0.88	-0.11	0.2	0.89	0.03	0.63	-0.15	0.32	0.63	0.89

Click cells to compare fundamentals

Arbutus Biopharma Account Relationship Matchups

Arbutus Biopharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	105.5M	137.1M	204.5M	195.4M	144.4M	124.4M
Other Current Liab	253K	5.8M	7.3M	20.5M	9.9M	10.4M
Total Current Liabilities	7.8M	9.5M	11.2M	32.9M	22.5M	23.6M
Total Stockholder Equity	72.7M	102.0M	169.4M	136.9M	106.0M	93.5M
Property Plant And Equipment Net	11.4M	9.3M	8.1M	6.8M	6.1M	4.8M
Net Debt	(28.4M)	(49.3M)	(106.7M)	(28.6M)	(17.6M)	(18.4M)
Retained Earnings	(970.1M)	(1.0B)	(1.1B)	(1.2B)	(1.3B)	(1.2B)
Cash	31.8M	52.3M	109.3M	30.8M	26.3M	39.9M
Non Current Assets Total	11.7M	9.4M	43.8M	44.3M	12.4M	11.8M
Non Currrent Assets Other	293K	44K	61K	103K	92.7K	88.1K
Cash And Short Term Investments	90.8M	123.3M	155.3M	146.9M	126.0M	73.6M
Net Receivables	1.2M	1.3M	899K	1.4M	1.8M	1.3M
Common Stock Total Equity	898.5M	985.9M	1.3B	1.3B	1.5B	1.6B
Common Stock Shares Outstanding	57.1M	75.8M	106.2M	150.9M	166.0M	174.3M
Short Term Investments	59.0M	71.0M	46.0M	116.1M	99.7M	104.7M
Liabilities And Stockholders Equity	105.5M	137.1M	204.5M	195.4M	144.4M	124.4M
Non Current Liabilities Total	25.0M	25.6M	23.8M	25.7M	15.9M	25.0M
Other Current Assets	1.8M	6.2M	8.9M	2.9M	4.2M	4.5M
Other Stockholder Equity	55.2M	60.8M	65.5M	72.4M	81.3M	85.3M
Total Liab	32.8M	35.1M	35.0M	58.6M	38.4M	31.0M
Property Plant And Equipment Gross	11.4M	9.3M	8.1M	6.8M	18.0M	18.9M
Total Current Assets	93.8M	127.7M	160.7M	151.1M	132.0M	76.6M
Common Stock	898.5M	985.9M	1.3B	1.3B	1.3B	1.4B
Other Liab	21.9M	23.0M	21.6M	23.9M	27.5M	18.6M
Net Tangible Assets	(64.5M)	(47.4M)	169.4M	136.9M	157.4M	165.2M
Accounts Payable	2.4M	3.0M	3.2M	3.5M	3.2M	2.5M
Retained Earnings Total Equity	(970.1M)	(1.0B)	(1.1B)	(1.2B)	(1.1B)	(1.0B)
Preferred Stock Total Equity	49.8M	126.1M	137.3M	149.4M	171.8M	180.4M
Accumulated Other Comprehensive Income	(48.2M)	(48.2M)	(48.3M)	(50.5M)	(48.4M)	(46.0M)
Property Plant Equipment	8.7M	6.9M	6.0M	5.1M	5.8M	4.5M
Capital Surpluse	55.2M	60.8M	65.5M	72.4M	83.3M	53.5M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arbutus Stock Analysis

When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC